Clinical Trial Update: Proof-of-Concept Trial on Selective Removal of sFlt-1 in Pregnant Women With Preeclampsia Via Apheresis [NA]

View source ↗

Summary

A completed proof-of-concept clinical trial evaluated selective removal of soluble fms-like tyrosine kinase-1 (sFlt-1) in pregnant women with preeclampsia using…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Preeclampsia

Drugs mentioned

• SFLT-1 selective apheresis device (selective removal of soluble fms-like tyrosine kinase-1 (sFlt-1) via apheresis)

Snippet

Sponsor: Miltenyi Biomedicine GmbH | Conditions: Preeclampsia | NA | Status: COMPLETED